Abstract
Degeneration of cortical glutamatergic projections may contribute to the cognitive decline in Alzheimer disease (AD). To evaluate whether 1glutamate system stimulation might confer symptomatic benefit, we administered D-cycloserine, a putative partial indirect agonist at certain N-methyl-D-aspartate (NMDA) glutamate receptors, to 12 patients with probable AD. The patients (seven men, five women) had a mean age of 65 ± 8.4 years; Mini Mental State Examination scores ranged from 15 to 25. A dose escalation phase, in which cycloserine was given in daily oral doses from 25 to 500 mg (total of six dose levels, 1 week per dose), was followed by a 'best dose' crossover comparison with placebo under double-blind conditions. The crossover phase consisted of 2 weeks of cycloserine and 2 weeks of placebo, separated by a 1-week washout period. We observed no significant or consistent effect on neuropsychological outcome measures. The results suggest that short-term potentiation of NMDA-mediated glutamatergic transmission may not prove useful in the symptomatic treatment of Alzheimer dementia.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 198-205 |
| Number of pages | 8 |
| Journal | Alzheimer Disease and Associated Disorders |
| Volume | 8 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jan 1 1994 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Clinical Psychology
- Gerontology
- Geriatrics and Gerontology
- Psychiatry and Mental health
Cite this
}
D-Cycloserine treatment of Alzheimer disease. / Randolph, C.; Roberts, J. W.; Tierney, M. C.; Bravi, D.; Mouradian, M Maral; Chase, T. N.
In: Alzheimer Disease and Associated Disorders, Vol. 8, No. 3, 01.01.1994, p. 198-205.Research output: Contribution to journal › Article
TY - JOUR
T1 - D-Cycloserine treatment of Alzheimer disease
AU - Randolph, C.
AU - Roberts, J. W.
AU - Tierney, M. C.
AU - Bravi, D.
AU - Mouradian, M Maral
AU - Chase, T. N.
PY - 1994/1/1
Y1 - 1994/1/1
N2 - Degeneration of cortical glutamatergic projections may contribute to the cognitive decline in Alzheimer disease (AD). To evaluate whether 1glutamate system stimulation might confer symptomatic benefit, we administered D-cycloserine, a putative partial indirect agonist at certain N-methyl-D-aspartate (NMDA) glutamate receptors, to 12 patients with probable AD. The patients (seven men, five women) had a mean age of 65 ± 8.4 years; Mini Mental State Examination scores ranged from 15 to 25. A dose escalation phase, in which cycloserine was given in daily oral doses from 25 to 500 mg (total of six dose levels, 1 week per dose), was followed by a 'best dose' crossover comparison with placebo under double-blind conditions. The crossover phase consisted of 2 weeks of cycloserine and 2 weeks of placebo, separated by a 1-week washout period. We observed no significant or consistent effect on neuropsychological outcome measures. The results suggest that short-term potentiation of NMDA-mediated glutamatergic transmission may not prove useful in the symptomatic treatment of Alzheimer dementia.
AB - Degeneration of cortical glutamatergic projections may contribute to the cognitive decline in Alzheimer disease (AD). To evaluate whether 1glutamate system stimulation might confer symptomatic benefit, we administered D-cycloserine, a putative partial indirect agonist at certain N-methyl-D-aspartate (NMDA) glutamate receptors, to 12 patients with probable AD. The patients (seven men, five women) had a mean age of 65 ± 8.4 years; Mini Mental State Examination scores ranged from 15 to 25. A dose escalation phase, in which cycloserine was given in daily oral doses from 25 to 500 mg (total of six dose levels, 1 week per dose), was followed by a 'best dose' crossover comparison with placebo under double-blind conditions. The crossover phase consisted of 2 weeks of cycloserine and 2 weeks of placebo, separated by a 1-week washout period. We observed no significant or consistent effect on neuropsychological outcome measures. The results suggest that short-term potentiation of NMDA-mediated glutamatergic transmission may not prove useful in the symptomatic treatment of Alzheimer dementia.
UR - http://www.scopus.com/inward/record.url?scp=0028048327&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028048327&partnerID=8YFLogxK
U2 - 10.1097/00002093-199408030-00006
DO - 10.1097/00002093-199408030-00006
M3 - Article
C2 - 7986489
AN - SCOPUS:0028048327
VL - 8
SP - 198
EP - 205
JO - Alzheimer Disease and Associated Disorders
JF - Alzheimer Disease and Associated Disorders
SN - 0893-0341
IS - 3
ER -